Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524580 | 0.83 | RXRA (0.42) | CTSSCTSKJAK2 | |
| SCHEMBL12545623 | 0.83 | RXRA (0.41) | CTSSCTSK | |
| SCHEMBL15344150 | 0.82 | CYP2A6 (0.48) | TGFBR1CYP2A6 | |
| SCHEMBL17234420 | 0.77 | ATP1A1 (0.45) | TGFBR1MAPKAPK2 | |
| SCHEMBL12761250 | 0.76 | GP6 (0.37) | — | |
| SCHEMBL17426496 | 0.76 | TGFBR1 (0.43) | PIM1TGFBR1MAPKAPK2CTSSCTSK | |
| SCHEMBL18852462 | 0.75 | MAP4K4 (0.34) | — | |
| SCHEMBL23879673 | 0.73 | BRD4 (0.47) | PIM1TGFBR1MAPKAPK2CTSSCTSK | |
| SCHEMBL14054103 | 0.73 | ASIC3 (0.53) | PIM1TGFBR1MAPKAPK2CYP2A6 | |
| SCHEMBL2609361 | 0.73 | PIM1 (0.48) | PIM1TGFBR1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PIM1 1335/4885TGFBR1 4545/4885MAPKAPK2 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.